Trials / Completed
CompletedNCT01417000
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Aduro Biotech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GVAX Pancreas | |
| BIOLOGICAL | CRS-207 | |
| DRUG | Cyclophosphamide |
Timeline
- Start date
- 2011-09-21
- Primary completion
- 2016-10-01
- Completion
- 2017-02-10
- First posted
- 2011-08-16
- Last updated
- 2018-05-08
- Results posted
- 2018-05-08
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01417000. Inclusion in this directory is not an endorsement.